Researchers have access to printed microarray design services, custom in-situ synthesised oligonucleotide microarrays, microarray scanner, and gene expression data analysis system
Agilent Technologies has announced that Abgenix has evaluated and adopted Agilent's custom microarray platform for genomic research.
Under the agreement, Abgenix researchers have access to Agilent's complete printed microarray solution portfolio comprising microarray design services, custom in-situ synthesised oligonucleotide microarrays with SurePrint technology, 48-slide DNA microarray scanner and the Rosetta Resolver gene expression data analysis system.
Abgenix has been qualifying the platform and will now use Agilent's microarray tools in the development of therapeutic monoclonal antibodies.
No further details of the agreement were disclosed.
"The Agilent microarray technology further enhances our ability to effectively apply our antibodies to the validation of genomic targets," said Geoffrey Davis, chief scientific officer at Abgenix. "Agilent's printed microarray solution portfolio and unique 60-mer custom microarray capabilities continue to attract research organisations like Abgenix, who want fast access to affordable, high-quality custom microarrays that can be tailored to their research needs," said Barney Saunders, vice president and general manager of Agilent's BioResearch Solutions organisation.
"We're excited to be working with Abgenix to help further its ground-breaking gene expression studies and antibody therapeutics R and D."
